Journal
BIOMATERIALS
Volume 35, Issue 9, Pages 3052-3059Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2013.12.031
Keywords
Pathological angiogenesis; Vascular endothelial growth factor; Choroidal neovascularization; Retinal neovascularization; Age-related macular degeneration; Diabetic retinopathy
Funding
- National Research Foundation of Korea
- Korean Government [NRF-2012-M2A2A7047948, NRF-2012-K1A1A2048701, 2009-0090895, 2012-0009544, 2012-0006019]
- Seoul National University [800-20130338]
Ask authors/readers for more resources
Age-related macular degeneration and diabetic retinopathy are leading causes of blindness. Vascular endothelial growth factor (VEGF) is known to be the main factor that induces pathological angiogenesis in these diseases. In this study, we investigate the therapeutic potential and safety profiles of high-affinity peptides targeting VEGF which are identified using an 'aptide' technology. We show that two VEGF-binding aptides, APT(VEGF1) and APT(VEGF2), demonstrate high binding affinity and specificity to VEGF. Furthermore, they suppress VEGF-induced activation of VEGF receptor-2, in vitro angiogenesis, and in vivo pathological choroidal and retinal neovascularization. Despite potent anti-angiogenic effects, both VEGF-binding aptides do not induce any definite toxicity at the level of cellular viability, histological integrity, and gene expression. Our data show the therapeutic potential of VEGF-binding peptides for the treatment of choroidal and retinal neovascularization. (C) 2013 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available